Compositions and methods for administering Borrelia DNA
US6451769B1 · kind B1 · utility
Assignees
Inventors
Key dates
| Filing date | Oct 15, 1998 |
| Grant date | Sep 17, 2002 |
| Priority date | — |
| Expiry date | Oct 15, 2018 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S977/804
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a vaccine against Lyme Disease or its causative agent Borrelia burgdorferi (sensu stricto or sensu lato) containing a plasmid a DNA encoding a promoter for driving expression in a mammalian cell, DNA encoding a leader peptide for facilitating secretion/release of a prokaryotic protein sequence from a mammalian cell, a DNA encoding Borrelia OspA or OspB, and a DNA encoding a terminator. Disclosed too is an immunogenic composition against Lyme Disease or its causative agent Borrelia burgdorferi (sensu stricto or sensu lato) containing a plasmid comprising a DNA encoding a promoter for driving expression in a mammalian cell, DNA encoding a leader peptide for facilitating secretion/release of a prokaryotic protein sequence from a mammalian cell, a DNA encoding a Borrelia OspC, and a DNA encoding a terminator. And, methods for making and using such vaccines and the immunogenic composition are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.